Altimmune's stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss
Altimmune Inc. (ALT) shares rallied more than 40% in the extended session Thursday after the clinical-stage biopharma company said 391 people enrolled in a trial of its obesity drug pemvidutide lost weight taking the pill in conjunction with diet and exercise. More than 50% of enrollees achieved at least 15% weight loss and more than 30% of people achieved at least 20% weight loss on certain doses of the drug, the company said. "As in prior clinical trials, pemvidutide resulted in robust reductions in serum lipids and improvements in blood pressure without imbalances in cardiac events, arrhythmias or clinically meaningful increases in heart rate," Altimmune said. Nausea and vomiting were most of the side effects, the company said. "The level of weight loss achieved at 48 weeks in this trial has been shown to reverse the key complications of obesity," Chief Medical Officer Scott Harris said in a statement. "It is also important to recognize the safety profile of pemvidutide observed to date," he said. Chief Executive Vipin K. Garg said it was an "important day for Altimmune and we couldn't be more pleased with these results." Altimmune shares ended the regular trading day up 1%.
-Claudia Assis
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-30-23 1642ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst